ALK-Abelló Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Peter Halling

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.9yrs
CEO ownership	n/a
Management average tenure	1.8yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO

Peter Halling (47 yo)

1.9yrs

Tenure

Mr. Peter Halling is President & Chief Executive Officer of ALK-Abelló A/S from 2023. Mr. Peter Halling served as Chief Executive Officer at Fertin Pharma A/S since August 2020. He has an extensive experie...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Claus Solje	Executive VP	1.5yrs	DKK 14.86m	no data
Søren Niegel	Executive VP of Commercial Operations & Member of Management Board	12.6yrs	DKK 6.51m	0.036% DKK 12.8m
Henriette Mersebach	Executive VP Research & Development & Member of Management Board	1.8yrs	DKK 7.18m	no data
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	no data	DKK 350.00k	no data
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	no data	DKK 270.00k	no data
Peter Halling	President & CEO	1.9yrs	no data	no data
Per Plotnikof	VP of Corporate Communications	no data	no data	no data
Jacob Glenting	Senior Vice President of Global Strategy & Corporate Development	less than a year	no data	no data
Lika Thiesen	Executive Vice President of Global People & Organisation	less than a year	no data	no data
Hendrik Kees Nolte	Senior Vice President of Research & Development - North America and International Markets	7.8yrs	no data	no data
Christian Houghton	Executive Vice President of Product Supply	5.9yrs	no data	no data
Peter Andersen	Senior Vice President of Global Research & Drug Discovery	no data	no data	no data

1.8yrs

Average Tenure

53yo

Average Age

Experienced Management: 0OIR's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	13.9yrs	DKK 350.00k	no data
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	1.8yrs	DKK 270.00k	no data
Jesper Hoiland	Independent Director	1.8yrs	DKK 366.00k	no data
Lene Skole-Sorensen	Vice Chairman of the Board	10.9yrs	DKK 900.00k	no data
Anders Hedegaard	Independent Chairman of the Board	4.8yrs	DKK 1.33m	no data
Lars Holmqvist	Director	9.8yrs	DKK 446.00k	no data
Gitte Aabo	Independent Director	3.8yrs	DKK 523.00k	no data
Alan Main	Independent Director	2.8yrs	DKK 450.00k	no data
Bertil Lindmark	Independent Director	3.8yrs	DKK 500.00k	no data
Nanna Carlson	Employee Representative Director	5.8yrs	DKK 350.00k	no data
Johan Smedsrud	Employee Representative Director	5.8yrs	DKK 350.00k	no data

4.8yrs

Average Tenure

61yo

Average Age

Experienced Board: 0OIR's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/18 03:47
End of Day Share Price	2024/12/18 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ALK-Abelló A/S is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Alexandru Cogut	Bryan Garnier & Co
Jesper Ilsoe	Carnegie Investment Bank AB

ALK-Abelló Management

Management criteria checks 1/4

Key information

Recent management updates

Insider recently sold kr.9.0m worth of stock

Alk-Abelló A/S Announces Executive Changes

ALK Announces Management Changes

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Recent updates

Alk-Abello A/S Approves in Europe for Treatment of Young Children

Third quarter 2024 earnings released: EPS: kr.0.95 (vs kr.0.53 in 3Q 2023)

ALK Announces U.S. FDA Approval of New AccuTest Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis

Second quarter 2024 earnings released: EPS: kr.0.90 (vs kr.0.30 in 2Q 2023)

ALK-Abelló A/S Revises Earnings Guidance for the 2024

Now 21% undervalued after recent price drop

ALK Presents Positive Phase 3 Paediatric Trial Data Offering New Hope for Children with Respiratory Allergy

Now 21% undervalued

Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review

Investor sentiment improves as stock rises 17%

First quarter 2024 earnings released

ALK-Abelló A/S Updates Revenue Guidance for the Year 2024

Insider recently sold kr.9.0m worth of stock

Full year 2023 earnings released

Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024

Investor sentiment improves as stock rises 36%

Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review

ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet

ALK-Abelló A/S to Report Q2, 2024 Results on Aug 23, 2024

Investor sentiment improves as stock rises 58%

Investor sentiment improves as stock rises 60%

Third quarter 2023 earnings released: EPS: kr.0.50 (vs kr.0.20 in 3Q 2022)

ALK-Abelló A/S to Report Fiscal Year 2023 Results on Feb 08, 2024

Alk-Abelló A/S Provides Earnings Guidance for the Year 2023

Investor sentiment improves as stock rises 87%

New major risk - Share price stability

Investor sentiment improves as stock rises 92%

Investor sentiment improves as stock rises 79%

ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet

Investor sentiment improves as stock rises 81%

Investor sentiment improves as stock rises 80%

ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023

Investor sentiment improves as stock rises 102%

Investor sentiment improves as stock rises 111%

Investor sentiment improves as stock rises 106%

Investor sentiment deteriorates as stock falls 16%

Alk-Abelló A/S Announces Executive Changes

Now 20% undervalued after recent price drop

Alk Announces Top-Line Results from A Phase 3 Paediatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis

Investor sentiment improves as stock rises 83%

Investor sentiment improves as stock rises 71%

Now 21% undervalued after recent price drop

ALK-Abelló A/S Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released

Investor sentiment improves as stock rises 80%

Now 23% undervalued after recent price drop

Investor sentiment improves as stock rises 43%

Investor sentiment improves as stock rises 49%

Investor sentiment improves as stock rises 40%

Now 23% undervalued

Investor sentiment improves as stock rises 44%

ALK Announces Management Changes

Full year 2022 earnings released

ALK-Abelló A/S Provides Revenue Guidance for the Full Year 2023

Investor sentiment improves as stock rises 51%

U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Investor sentiment improved over the past week

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

Investor sentiment improved over the past week

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: kr.0.24 (vs kr.0.17 in 3Q 2021)

Less than half of directors are independent

Third quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Investor sentiment improved over the past week